Clinical practice guideline reveals strategies for preventing and managing opportunistic infections in inflammatory bowel disease, highlighting safety protocols for advanced therapies.
INTRODUCTION : The introduction and broad use of new immunosuppressive agents, including biologic agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease [IBD] in recent decades. With such immunosuppression, the potential for opportunistic infection is a key safety concern. [...]
No takes yet. Share an insight, caveat, or question.
Kucharzik et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: